David Avigan
Beth Israel Deaconess Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Avigan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07374029 · Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLDavid Avigan · recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse · principal investigator
- Ph1NCT06799026 · A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaDavid Avigan · recruiting · Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1/Ph2NCT02204085 · A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid LeukemiaBeth Israel Deaconess Medical Center · completed · Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia · principal investigator
- Ph2NCT01441765 · PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell VaccineBeth Israel Deaconess Medical Center · terminated · Renal Cell Carcinoma · principal investigator
- Ph2NCT01067287 · Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell TransplantationBeth Israel Deaconess Medical Center · completed · Multiple Myeloma · principal investigator
- N/ANCT00801320 · Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal CancerBeth Israel Deaconess Medical Center · completed · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT00799110 · Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodBeth Israel Deaconess Medical Center · terminated · Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph1/Ph2NCT00626860 · The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance MelanomaBeth Israel Deaconess Medical Center · completed · Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT00625755 · A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell CarcinomaBeth Israel Deaconess Medical Center · completed · Renal Cell Carcinoma · principal investigator
- Ph1/Ph2NCT00622401 · Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12Beth Israel Deaconess Medical Center · terminated · Breast Cancer · principal investigator
- Ph1NCT00459069 · The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple MyelomaBeth Israel Deaconess Medical Center · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00458536 · Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSFBeth Israel Deaconess Medical Center · completed · Renal Cancer · principal investigator
- Ph1NCT00458653 · Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple MyelomaBeth Israel Deaconess Medical Center · completed · Multiple Myeloma · principal investigator
- Ph2NCT00393380 · Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated DonorThe Emmes Company, LLC · terminated · Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis · principal investigator
- Ph1NCT00299767 · Phase I Study of Sequential Cord Blood TransplantsMassachusetts General Hospital · completed · Lymphoma, Leukemia, Multiple Myeloma · principal investigator
- Ph2NCT00085397 · Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaDana-Farber Cancer Institute · unknown · Melanoma (Skin) · principal investigator
- Ph1NCT00003412 · Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell TransplantationBeth Israel Deaconess Medical Center · unknown · Breast Cancer · study chair
- Ph1/Ph2NCT00006123 · Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast CancerBeth Israel Deaconess Medical Center · withdrawn · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Personalized Adoptive T-cell Therapy for AMLR01CA262629 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2021 to 2026 · $728,501 awarded in 2026Same name and institution; not confirmed by an ID
- Personalized vaccine for patients with AMLR01CA212649 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2017 to 2022 · $653,338 awarded in 2022Same name and institution; not confirmed by an ID
- Targeting PML for Leukemia TherapyR01CA142874 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2020 · $456,984 awarded in 2020Same name and institution; not confirmed by an ID
- Directed Purinergic Signaling as Immunotherapy in LeukemiaR21CA221702 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2018 to 2019 · $184,603 awarded in 2019Same name and institution; not confirmed by an ID
- RHIL-12 FOLLOWING HIGH DOSE CHEMOTHERAPYR55CA079433 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 1998 · $84,000 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- DF/HCC Kidney Cancer Project 2: Optimizing Anti-PD1 Based Therapy in High Risk and Metastatic RCCP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Arlene H. Sharpe · fiscal years 2018 to 2026Named on NCT01441765
- U01CA062490RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00622401
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00622401
- U54HL081030RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00393380
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:36 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- 1,575 citationsRCR 84.7
- Interleukin-2 and regulatory T cells in graft-versus-host disease.N Engl J Med · 2011937 citationsRCR 22.1
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol · 2016874 citationsRCR 27.2
- 730 citationsRCR 17.8
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation.N Engl J Med · 2016514 citationsRCR 15.5
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med · 2018426 citationsRCR 14.6
- 417 citationsRCR 37.4
- 376 citationsRCR 9.5
- 229 citationsRCR 6.0
- Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.Clin Cancer Res · 2004190 citationsRCR 3.4